CA2943149C - Tolerogenic compositions comprising and uses thereof - Google Patents

Tolerogenic compositions comprising and uses thereof Download PDF

Info

Publication number
CA2943149C
CA2943149C CA2943149A CA2943149A CA2943149C CA 2943149 C CA2943149 C CA 2943149C CA 2943149 A CA2943149 A CA 2943149A CA 2943149 A CA2943149 A CA 2943149A CA 2943149 C CA2943149 C CA 2943149C
Authority
CA
Canada
Prior art keywords
polypeptide
allergen
vaca
formulation
vac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2943149A
Other languages
English (en)
French (fr)
Other versions
CA2943149A1 (en
Inventor
Anne Mueller
Daniela ENGLER-ANDERS
Christian Taube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Leids Universitair Medisch Centrum LUMC
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie, Leids Universitair Medisch Centrum LUMC filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CA2943149A1 publication Critical patent/CA2943149A1/en
Application granted granted Critical
Publication of CA2943149C publication Critical patent/CA2943149C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2943149A 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof Active CA2943149C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14153365.3A EP2902037A1 (en) 2014-01-31 2014-01-31 Tolerogenic compositions comprising and uses thereof
EP14153365.3 2014-01-31
PCT/IB2015/050703 WO2015114575A1 (en) 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof

Publications (2)

Publication Number Publication Date
CA2943149A1 CA2943149A1 (en) 2015-08-06
CA2943149C true CA2943149C (en) 2022-07-12

Family

ID=50028895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2943149A Active CA2943149C (en) 2014-01-31 2015-01-30 Tolerogenic compositions comprising and uses thereof

Country Status (8)

Country Link
US (1) US9999660B2 (enExample)
EP (2) EP2902037A1 (enExample)
JP (1) JP6563937B2 (enExample)
AU (1) AU2015212357B2 (enExample)
CA (1) CA2943149C (enExample)
DK (1) DK3099314T3 (enExample)
ES (1) ES2806773T3 (enExample)
WO (1) WO2015114575A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166986B2 (en) 2014-01-31 2021-11-09 Universitat Zurich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4669337A1 (en) * 2023-09-26 2025-12-31 Atopia Therapeutics Sa USEFUL AGENTS FOR THE PREVENTION OR TREATMENT OF ALLERGIC AND INFAMMATORY DISORDERS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004017A2 (en) * 2000-07-07 2002-01-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for preparing oral vaccines
JP2005506322A (ja) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
JP2004189730A (ja) * 2002-11-28 2004-07-08 Japan Science & Technology Agency 細胞死の抑制方法、細胞死抑制剤、及びその細胞死抑制剤を含む細胞死に起因する疾患の治療薬剤
US11166986B2 (en) 2014-01-31 2021-11-09 Universitat Zurich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease

Also Published As

Publication number Publication date
EP2902037A1 (en) 2015-08-05
AU2015212357B2 (en) 2020-05-28
EP3099314B1 (en) 2020-04-22
EP3099314A1 (en) 2016-12-07
ES2806773T3 (es) 2021-02-18
DK3099314T3 (da) 2020-07-20
US20170007683A1 (en) 2017-01-12
WO2015114575A1 (en) 2015-08-06
JP2017509597A (ja) 2017-04-06
US9999660B2 (en) 2018-06-19
CA2943149A1 (en) 2015-08-06
AU2015212357A1 (en) 2016-08-18
JP6563937B2 (ja) 2019-08-21

Similar Documents

Publication Publication Date Title
JP5191234B2 (ja) 免疫疾患の予防ないし治療剤および方法
CN101977929B (zh) 用于治疗变态反应的主要1类和2类螨变应原的低变应原性杂合蛋白
Kurup et al. Animal models of allergic bronchopulmonary aspergillosis
KR101469167B1 (ko) 봉독-ｐｌａ2를 포함하는 이상 조절 ｔ 세포 활성 저하 관련 질환의 치료 또는 예방용 약학적 조성물
US20160193319A1 (en) Flagellin Fusion Proteins and Use Thereof to Induce Immune Responses Against Pseudomonas aeruginosa
JP2011157380A (ja) 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
CA2943149C (en) Tolerogenic compositions comprising and uses thereof
US20090176696A1 (en) Methods And Compositions For Modulating An Immune Response
Macaubas et al. Respiratory tolerance in the protection against asthma
EP2892556A1 (en) Compositions and methods relating to the treatment of diseases
US5948413A (en) Method and vaccine for treatment of pythiosis insidiosi in humans and lower animals
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
US11166986B2 (en) Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
JP2015506975A (ja) 家畜の非ヒト哺乳動物における炎症性疾患の予防
JPWO1999040935A1 (ja) 新規な免疫異常性疾患予防・治療用剤
AU2004279209A1 (en) Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
WO2013134656A1 (en) Induction of th17 immune response
Zhang Research progress on the role of immune cells in Brucella infection
JP2009533478A (ja) 黄色ブドウ球菌感染症の治療用薬剤の製造のための活性成分としてｔｒａｐタンパク質自体の使用
US20170333551A1 (en) Use of superantigens for improving mucosal allergen specific immunotherapy in human beings
Chi-Yan Development of a mouse model of shrimp allergy
US20140220065A1 (en) Therapeutic application of s. pyogenes c-terminal peptide
CN104922659A (zh) 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
ORAL Mucosal tolerance and autoimmunity
WO2006109285A1 (en) Methods and compounds for the treatment of autoimmune diseases and chronic inflammatory conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200129

EEER Examination request

Effective date: 20200129